From cognitive chips to adaptive AI, deep tech is reshaping precision neurotherapeutics. With virtual twins and precision platforms, we’re closing the gap between clinical insight, personalised care and everyday digital life.
CogniChip
Combining all our expertise in one chip
CogniChip is the end goal of all we do at MindMaze Therapeutics. Every discovery we make brings it a step closer. Designed to simultaneously process and coordinate all the sensory and physical inputs a brain experiences, this cognitive platform will combine these elements to create a virtual self.
The applications of this digital twin are tremendously broad. As well as consolidating our digital therapy vision for healthcare, it will have a profound impact across every aspect of human life – transport, aviation, gaming, communications, and sports.
Artificial intelligence
Agentic precision neurotherapeutics solutions for the future of brain health
Harnessing data-driven insights and adaptive therapeutic intelligence to personalize care, enhance engagement and shape the next era of precision neurotherapeutics.
We are developing an intelligent, data-informed platform designed to enhance personalization, efficiency, and long-term scalability in precision neurotherapeutics. Built on validated clinical algorithms and one of the largest multimodal behavioral datasets in the field, our AI systems are being designed to support clinicians in monitoring engagement, identifying performance trends, and tailoring therapy plans more effectively, while also improving patient motivation and adherence across care settings.
As these capabilities evolve, intelligent patient- and clinician-facing assistants are expected to streamline key workflows, enhance therapeutic guidance, and help reduce barriers to treatment continuity—factors critical for real-world effectiveness and market adoption. To ensure clinical appropriateness, our roadmap emphasizes a hybrid AI architecture that prioritizes traceability, reliability, and alignment with clinical requirements. Deterministic expert models form the foundational decision layer, complemented by adaptive, data-driven intelligence to enhance responsiveness while maintaining auditability.
Over time, advanced generative and adaptive models will enable deeper personalization of therapeutic content and support structured exploration of digital–drug combinations, always subject to clinical validation and regulatory considerations. This structured, evidence-guided approach positions the company to expand therapeutic reach, improve operational efficiency, and unlock differentiated value across multiple segments of neurological care—reinforcing our long-term strategy to lead in intelligent, data-driven precision neurotherapeutics.